Showing 1 - 10 of 736
. Here we explore the importance within the biotechnology industry of the non-financial metrics firms used to convey value … was a change over time in the importance of various metrics in determining the value of a biotechnology firm. We find that … value. Our results also suggest that the biotechnology regime changed and the Nobel Prize lost its luster as a signal of …
Persistent link: https://www.econbiz.de/10012464045
North American Industry Classification System (NAICS) as biotechnology firms to estimate several Fama-French three factor …In the current study we find that biotechnology firms are exposed to greater financial risk than other industries and … capital over the 1982-2005 time period were 16.25 percent for biotechnology firms. Of course, these average estimates obscure …
Persistent link: https://www.econbiz.de/10012465042
Using data on over 900 firms for the period 1988-2000, we estimate the effect on phase-specific biotech and pharmaceutical R&D success rates of a firm's overall experience, its experience in the relevant therapeutic category; the diversification of its experience, and alliances with large and...
Persistent link: https://www.econbiz.de/10012469083
Scientist-entrepreneurs prominent in biotech and other high-technology industries view going public not as a cost-effective source of capital but as a cross between selling a now-proven innovation and winning a lottery. Unlike most empirical IPO analyses confined to those firms that go public,...
Persistent link: https://www.econbiz.de/10012469760
Commercializing knowledge involves transfer from discovering scientists to those who will develop it commercially. New codes and formulae describing discoveries develop slowly - with little incentive if value is low and many competing opportunities if high. Hence new knowledge remains naturally...
Persistent link: https://www.econbiz.de/10012470219
, such as intellectual human capital, can predict where and when biotechnology enterprises emerge and agglomerate. Density … more conjectural than empirically tenable. We argue and demonstrate for biotechnology that an alternative model based on … essentially uncorrelated with the panel data on biotechnology entry by year and region while the combined model has correlation …
Persistent link: https://www.econbiz.de/10012472394
In this paper, we examine the determinants of control rights in technology strategic alliances between biotechnology … firms and pharmaceutical corporations, as well as with other biotechnology firms. We undertake three clinical studies and an …
Persistent link: https://www.econbiz.de/10012472804
.S. biotechnology enterprises during 1976-1989. Using a linked cross-section/time- series panel data set, we find that the timing and … structures. We believe biotechnology may be prototypical of the birth patterns in other innovative industries …
Persistent link: https://www.econbiz.de/10012474283
We evaluate the effects of state-provided financial incentives for biotech companies, which are part of a growing trend of placed-based policies designed to spur innovation clusters. We estimate that the adoption of subsidies for biotech employers by a state raises the number of star biotech...
Persistent link: https://www.econbiz.de/10012459367
breakthroughs (e.g., biotechnology, lasers, semiconductors, nanotechnology). Unless congruent with incumbents' science and …
Persistent link: https://www.econbiz.de/10012469767